Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"IRICoR","sponsor":"Universit\u00e9 de Montr\u00e9al","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IRICoR, UdeM, IRIC and Valence Discovery collaborate to design novel drug candidates","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"CANADA","productType":"Undisclosed","productStatus":"Undisclosed","date":"March 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by IRICoR

    Menu

    IRICoR

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              IRICoR

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IRICoR, UdeM, IRIC and Valence Discovery collaborate to design novel drug candidates

              Details:

              The collaboration builds on research from the team of Dr. Daniel Levesque at UdeM, and focuses on the design of highly selective modulators of the Nur77/RXR nuclear receptor complex, a promising new pharmacological target for movement disorders.

              Lead Product(s): Undisclosed

              Therapeutic Area: Neurology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Partner/Sponsor/Collaborator: Université de Montréal

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration March 10, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY